These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 30001170)

  • 1. IPH4102, a monoclonal antibody directed against the immune receptor molecule KIR3DL2, for the treatment of cutaneous T-cell lymphoma.
    Van Der Weyden C; Bagot M; Neeson P; Darcy PK; Prince HM
    Expert Opin Investig Drugs; 2018 Aug; 27(8):691-697. PubMed ID: 30001170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial.
    Bagot M; Porcu P; Marie-Cardine A; Battistella M; William BM; Vermeer M; Whittaker S; Rotolo F; Ram-Wolff C; Khodadoust MS; Bensussan A; Paturel C; Bonnafous C; Sicard H; Azim HA; Kim YH
    Lancet Oncol; 2019 Aug; 20(8):1160-1170. PubMed ID: 31253572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IPH4102, a humanized KIR3DL2 antibody with potent activity against cutaneous T-cell lymphoma.
    Marie-Cardine A; Viaud N; Thonnart N; Joly R; Chanteux S; Gauthier L; Bonnafous C; Rossi B; Bléry M; Paturel C; Bensussan A; Bagot M; Sicard H
    Cancer Res; 2014 Nov; 74(21):6060-70. PubMed ID: 25361998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KIR3DL2 (CD158k) is a potential therapeutic target in primary cutaneous anaplastic large-cell lymphoma.
    Battistella M; Janin A; Jean-Louis F; Collomb C; Leboeuf C; Sicard H; Bonnafous C; Dujardin A; Ram-Wolff C; Kadin ME; Bensussan A; Bagot M; Michel L
    Br J Dermatol; 2016 Aug; 175(2):325-33. PubMed ID: 27037558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New Targeted Treatments for Cutaneous T-cell Lymphomas.
    Bagot M
    Indian J Dermatol; 2017; 62(2):142-145. PubMed ID: 28400633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic Antibodies to KIR3DL2 and Other Target Antigens on Cutaneous T-Cell Lymphomas.
    Schmitt C; Marie-Cardine A; Bensussan A
    Front Immunol; 2017; 8():1010. PubMed ID: 28912774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel and Future Therapeutic Drugs for Advanced Mycosis Fungoides and Sézary Syndrome.
    Oka T; Miyagaki T
    Front Med (Lausanne); 2019; 6():116. PubMed ID: 31192214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cutaneous T cell Lymphoma: an Update on Pathogenesis and Systemic Therapy.
    Chung CG; Poligone B
    Curr Hematol Malig Rep; 2015 Dec; 10(4):468-76. PubMed ID: 26626770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal antibodies against cutaneous T-cell lymphomas.
    Alaibac M
    Expert Opin Biol Ther; 2017 Dec; 17(12):1503-1510. PubMed ID: 28829215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of selective retinoic acid receptor- and retinoic X receptor-mediated efficacy, tolerance, and survival in cutaneous t-cell lymphoma.
    Querfeld C; Rosen ST; Guitart J; Rademaker A; Fung BB; Posten W; Kuzel TM
    J Am Acad Dermatol; 2004 Jul; 51(1):25-32. PubMed ID: 15243520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KIR3DL2 in cutaneous T-cell lymphoma: from a promising biomarker to a potential therapeutic target.
    Sun J; Wang Y
    Br J Dermatol; 2020 Jun; 182(6):1325-1326. PubMed ID: 31808144
    [No Abstract]   [Full Text] [Related]  

  • 13. New biotherapies for the treatment of cutaneous T-cell lymphomas.
    de Masson A
    Presse Med; 2022 Mar; 51(1):104110. PubMed ID: 35026391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis.
    Duvic M; Tetzlaff MT; Gangar P; Clos AL; Sui D; Talpur R
    J Clin Oncol; 2015 Nov; 33(32):3759-65. PubMed ID: 26261247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Epidermotropic T cell lymphomas as models for tumor progression].
    Bagot M; Bensussan A
    Med Sci (Paris); 2006 Feb; 22(2):192-6. PubMed ID: 16457762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KIR3DL2/CpG ODN interaction mediates Sézary syndrome malignant T cell apoptosis.
    Ghazi B; Thonnart N; Bagot M; Bensussan A; Marie-Cardine A
    J Invest Dermatol; 2015 Jan; 135(1):229-237. PubMed ID: 25007046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-KIR3DL2 therapy in the treatment of Sézary syndrome.
    Quaglino P
    Lancet Oncol; 2019 Aug; 20(8):1048-1049. PubMed ID: 31253571
    [No Abstract]   [Full Text] [Related]  

  • 19. Cutaneous T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease.
    Argnani L; Broccoli A; Zinzani PL
    Cancer Treat Rev; 2017 Dec; 61():61-69. PubMed ID: 29102679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel therapies for cutaneous T-cell lymphoma: what does the future hold?
    Guenova E; Hoetzenecker W; Rozati S; Levesque MP; Dummer R; Cozzio A
    Expert Opin Investig Drugs; 2014 Apr; 23(4):457-67. PubMed ID: 24397291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.